All results
6 results for randomized phase iii trial evaluating pathologic complete response rates patients
-
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cance
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy for Limited mCRC(ERASur)
This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer…
- Ages
- 18 Years - N/A
- Sexes
- All
-
mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Tx of Metastatic HER2- GE Adendocarcinoma
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil,…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Immunotherapy for Patients With Advanced Kidney Cancer, The PDIGREE Study
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Genomic-Risk Stratified Txs for Unfavorable Intermediate Risk Prostate Cancer (Guidance)
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk)…
- Ages
- 18 Years - N/A
- Sexes
- Male
-
Testing Triapine w/ Targeted Radiation-based LU177 vs Lu177 alone in pts w/ metastatic NETs
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking…
- Ages
- 18 Years - N/A
- Sexes
- All